Search

iSTAR Medical

Webinar Part 5: Results of European STAR-II Trial at 6 Months

Julián García-Feijoó, MD, PhD

Show Description +

Julián García-Feijoó, MD, PhD (Spain), reviews the European STAR-II clinical trial. Prof. García-Feijoó expands upon the similarities of the STAR-I trial and discusses the nuances of the study demographics. Patient qualified success rates at 6 months are also presented, along with the differences between medication free and on-medication patients, safety data, and adverse events. Six-month primary endpoint results from MINIject's European STAR-II trial showed powerful IOP and medication reduction. Read more in the Journal of Glaucoma, October 2020.

Posted: 11/11/2020

Keywords:

iSTAR Medical

Up Next

Webinar Part 6: Clinical Trial Results Q&A and Next Steps

Webinar Part 6: Clinical Trial Results Q&A and Next Steps

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Enhanced and Sustained IOP reduction with MINIject<sup>™</sup>

Enhanced and Sustained IOP reduction with MINIject^™

Iqbal Ike K. Ahmed, MD, FRCSC, Michel Vanbrabant, Steven Vold, MD

The Role of Supraciliary MIGS in the Glaucoma Treatment Paradigm

The Role of Supraciliary MIGS in the Glaucoma Treatment Paradigm

I. Paul Singh, MD

Consider the Supraciliary Space With MINIject

Consider the Supraciliary Space With MINIject

Joseph F. Panarelli, MD; and I. Paul Singh, MD

Effectiveness and Use of MINIject and What is New About MINIject S

Effectiveness and Use of MINIject and What is New About MINIject S

Leon Au, BSc, MBBS, FRCOphth

MINIject S: How it Influences Surgical Results and Patient Selection

MINIject S: How it Influences Surgical Results and Patient Selection

Tim Schultz, MD, PhD, FEBO

Question and Answer: MINIject Supraciliary MIGS Device

Question and Answer: MINIject Supraciliary MIGS Device

Joseph F. Panarelli, MD; Leon Au, BSc, MBBS, FRCOphth; and Tim Schultz, MD, PhD, FEBO

Advantages and Opportunities of the Supraciliary Space

Advantages and Opportunities of the Supraciliary Space

Steven R. Sarkisian Jr, MD

Patient Selection With MINIject: Who Can Benefit From Supraciliary MIGS?

Patient Selection With MINIject: Who Can Benefit From Supraciliary MIGS?

Karsten Klabe, MD

Real-World Experiences With MINIject

Real-World Experiences With MINIject

Faisal Ahmed, MD

STAR-GLOBAL 3-Year Results

STAR-GLOBAL 3-Year Results

I. Paul Singh, MD

Q&A: MINIject Supraciliary MIGS Device

Q&A: MINIject Supraciliary MIGS Device

Steven R. Sarkisian Jr, MD; Karsten Klabe, MD; Faisal Ahmed, MD; and I. Paul Singh, MD

Full Webinar: An Eye-Opening Update on MIGS

Full Webinar: An Eye-Opening Update on MIGS

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

European STAR-II Trial Results at One Year

European STAR-II Trial Results at One Year

Julián García-Feijoó, MD, PhD

A Closer Look at iSTAR Medical

A Closer Look at iSTAR Medical

iSTAR Medical

Introduction to MINIject™

Introduction to MINIject™

iSTAR Medical

Webinar Part 1: Where Do We Stand With MIGS?

Webinar Part 1: Where Do We Stand With MIGS?

Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 2: How Can We Leverage the Power of the Supraciliary Space?

Webinar Part 2: How Can We Leverage the Power of the Supraciliary Space?

Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD, Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 3: The MINIject™ Next-Generation Supraciliary Device

Webinar Part 3: The MINIject™ Next-Generation Supraciliary Device

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Webinar Part 4: Results of the STAR-I Trial at 24 Months

Webinar Part 4: Results of the STAR-I Trial at 24 Months

Philippe Denis, MD, PhD

Back to All Videos

Webinar Part 5: Results of European STAR-II Trial at 6 Months

Julián García-Feijoó, MD, PhD

Julián García-Feijoó, MD, PhD (Spain), reviews the European STAR-II clinical trial. Prof. García-Feijoó expands upon the similarities of the STAR-I trial and discusses the nuances of the study demographics. Patient qualified success rates at 6 months are also presented, along with the differences between medication free and on-medication patients, safety data, and adverse events. Six-month primary endpoint results from MINIject's European STAR-II trial showed powerful IOP and medication reduction. Read more in the Journal of Glaucoma, October 2020.

Posted: 11/11/2020

Keywords:

iSTAR Medical

About iSTAR Medical

Visit us online: istarmed.com

Follow iSTAR Medical